Axitinib/axitinib tablets combination regimen and contraindications

Axitinib is an oral targeted drug that mainly inhibits tumor angiogenesis by inhibiting the kinase activity of vascular endothelial growth factor receptor (VEGFR), thereby effectively treating metastatic renal cell carcinoma (mRCC). In clinical treatment, axitinib is often used in combination with other drugs to increase efficacy and reduce drug resistance problems. Common combination drug regimens include combination with immune checkpoint inhibitors and other targeted drugs, such as avelumab, pembrolizumab, etc.

A common combination regimen is axitinib combined with an immune checkpoint inhibitor (such asPD-1 or PD-L1 inhibitor). Immunotherapy works on tumor cells by enhancing the anti-tumor ability of the patient's own immune system. Combined with the vascular inhibitory effect of axitinib, it can attack tumors in multiple dimensions. This combination therapy can enhance the anti-tumor effect, improve patient survival rate, and reduce the risk of tumor recurrence.

In addition, axitinib can also be used in combination with other targeted drugs (such as ramucirumab, pembrolizumab, etc.). By combining targeted drugs with different mechanisms of action, the therapeutic effect can be increased and the adaptability and drug resistance of cancer cells can be reduced. The choice of treatment plan is usually based on the patient's condition, tumor characteristics, and patient's physical condition to ensure individualized treatment.

Axitinib also has some contraindications to its use. Pregnant and breastfeeding women should avoid the use of axitinib because the drug may have adverse effects on the fetus or infant. For patients with severe cardiovascular disease, especially those with a history of hypertension or heart disease, special caution is required when using axitinib, and blood pressure and heart function should be monitored regularly to avoid complications caused by elevated blood pressure.

Reference materials:https://en.wikipedia.org/wiki/Axitinib